Mannil, M., A. Solari, A. Leha, A. L. Pelayo-Negro, J. Berciano, B. Schlotter-Weigel, M. C. Walter, B. Rautenstrauss, T. J. Schnizer, A. Schenone, P. Seeman, C. Kadian, O. Schreiber, N. G. Angarita, G. M. Fabrizi, F. Gemignani, L. Padua, L. Santoro, A. Quattrone, G. Vita, D. Calabrese, CMT-TRIAAL/CMT-TRAUK Group, P. Young, M. Laurà, J. Haberlová, R. Mazanec, W. Paulus, T. Beissbarth, M. E. Shy, M. M. Reilly, D. Pareyson and M. W. Sereda: Selected items from the Charcot-Marie-Tooth (CMT) neuropathy score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. In: Neuromuscular Disorders 24, 1003-1017 (2014).
Fledrich, R., B. Schlotter-Weigel, T. J. Schnizer, S. P. Wichert, R. M. Stassart, G. Meyer zu Hörste, A. Klink, B. G. Weiss, U. Haag, M. C. Walter, B. Rautenstrauss, W. Paulus, M. J. Rossner and M. W. Sereda: A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. In: Brain 135, 1, 72-87 (2012).
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.